Results 141 to 150 of about 127,159 (238)

Evaluating the Impact of CYP1A2 Inhibition on the Pharmacokinetics of Savolitinib: A Phase 1 Open‐Label Study

Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
ABSTRACT Savolitinib is an oral, potent, selective CNS‐penetrant MET‐tyrosine kinase inhibitor that in vitro studies indicate is metabolized by cytochrome P450 (CYP) enzymes, including CYP1A2, and by non‐CYP enzymes, such as aldehyde oxidase (AO). Savolitinib primary metabolites, M2 and M3, are formed mainly by CYP1A2 and AO, respectively. This Phase 1,
Kowser Miah, Jitendar Reddy, Pradeep Sharma, Ike Igwegbe, Simon Nelson, Caitlin Muldoon, Ronald Goldwater, Karthick Vishwanathan   +7 more
wiley   +1 more source

T.P.2.09 Induced exon skipping in normal and mdx muscle

, 2008
Induced exon skipping to remove or by-pass protein truncating mutations in the dystrophin gene is emerging as a potential therapy for many cases of Duchenne muscular dystrophy. It has been proposed that the compromised sarcolemma of the dystrophic muscle
Meloni, P., Mitrpant, C., Steinhaus, J., Fletcher, S., Wilton, S.   +4 more
core  

Splicing Factor Mutations in Clonal Hematopoiesis and Progression to Myeloid Neoplasms

Cancer Science, Volume 117, Issue 10, Page 2609-2618, October 2026.
Splicing factor (SF)‐mutant CH is characterized by relatively late emergence and accelerated clonal expansion in older individuals. This review summarizes its clonal dynamics, disease‐associated consequences of SF mutations in myeloid neoplasms, and candidate mechanisms that may contribute to age‐dependent selection.
Yang Lyu, Yutong Zhang, Ayana Kon
wiley   +1 more source

Timing matters: Exon skipping therapy is most effective when initiated early in a mouse model of Duchenne muscular dystrophy. [PDF]

Mol Ther Nucleic Acids
Stenler S, Huang J, van Westering TLE, Coenen-Stass AML, Jad Y, Krjutškov K, El Andaloussi S, Wood MJA, Roberts TC.   +8 more
europepmc   +2 more sources

Clinical and Imaging Features of Tepotinib‐Induced Interstitial Lung Disease in the Post‐Marketing Setting in Japan

Cancer Science, Volume 117, Issue 10, Page 2827-2837, October 2026.
This article reports on the clinical and imaging features of tepotinib‐induced interstitial lung disease (ILD), which were evaluated by an ILD adjudication committee composed of external respiratory and radiology experts, and the committee expertly identified 35 patients with tepotinib‐induced ILD from spontaneous adverse event reports accumulated in ...
Terufumi Kato, Tomohisa Baba, Masahiro Endo, Shehla Endo, Eisuke Horii, Masahiko Kusumoto   +5 more
wiley   +1 more source

Pediatric Mediastinal Gray Zone Lymphoma With Germline TET2 Heterozygous Variant

Pediatric Blood &Cancer, Volume 73, Issue 11, November 2026.
Matthew R. Schuelke, Julia Wang, Haley Newman, Evelyn Kurpiewski, Anne Reilly, Susan R. Rheingold, Gerald Wertheim, Moe Takeda, Daniel J. Zheng, Kaitlin Devine   +9 more
wiley   +1 more source

mRNA Therapeutics for Skin Rejuvenation: From Aging Atlases to Clinical Translation

Experimental Dermatology, Volume 35, Issue 10, October 2026.
ABSTRACT Skin aging is a multifactorial process characterized by the progressive decline of tissue structure, function and regenerative capacity. Although numerous interventions have been developed to improve the clinical manifestations of aging, most primarily alleviate downstream consequences rather than directly targeting the molecular mechanisms ...
Fabiana Boncimino, Stefano Sol, Kristina Todorova, Anna Mandinova   +3 more
wiley   +1 more source

Exon Skipping of Cathepsin B [PDF]

Journal of Biological Chemistry, 2004
Kathrin Müntener, Roman Zwicky, Gabor Csucs, Jack Rohrer, Antonio Baici   +4 more
openaire   +1 more source

Exon-Skipping [PDF]

, 2018
openaire   +1 more source

Exon-skipping therapies for DMD in Kazakhstan: Progress and challenges. [PDF]

J Neuromuscul Dis
Jaxybayeva A, Myrzaliyeva B, Lepessova M, Tekebayeva L, Ayaganov D.   +4 more
europepmc   +1 more source